Effect of antifungal treatment in a murine model of blastoschizomycosis

International Journal of Antimicrobial Agents

Volumn 29, Issue 1, 2007, Pages 79-83

  Serena, Carolina ^a   Mariné, Marçal ^a   Marimon, Rita ^a   Pastor, Francisco Javier ^a   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Antifungal agents; Blastoschizomyces capitatus; Blastoschizomycosis; Geotrichum capitatum; Murine model

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; FUNGIZONA; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLASTOSCHIZOMYCES CAPITATUS; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; GEOTRICHUM CAPITATUM; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; LOW DRUG DOSE; MALE; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; SURVIVAL TIME; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUCONAZOLE; FLUCYTOSINE; GEOTRICHOSIS; GEOTRICHUM; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER; MALE; MICE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; SPLEEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 33845642565     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.08.025     Document Type: Article

References (19)

1. Martino P., Venditti M., Micozzi A., et al. Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients. Rev Infect Dis 12 (1990) 570-582
2. Girmenia C., Pagano L., Martino B., et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 43 (2005) 1818-1828
3. Martino R., Salavert M., Parody R., et al. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis 38 (2004) 335-341
4. Bouza E., and Muñoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 10 (2004) 76-85
5. Groll A.H., and Walsh T.J. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 7 (2001) 8-24
6. Girmenia C., Pizarelli G., D'Antonio D., et al. In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method. Antimicrob Agents Chemother 47 (2003) 3985-3988
7. D'Antonio D., Mazzoni A., Icone A., et al. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol 34 (1996) 753-755
8. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 26 (1998) 198-202
9. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. 2nd ed. Approved standard M27-A2. Wayne, PA: NCCLS; 2002.
10. Graybill J.R., Bocanegra R., Najvar L.K., et al. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 42 (1998) 2467-2473
11. Graybill J.R., Najvar L.K., Holmberg J.D., et al. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob Agents Chemother 39 (1995) 924-929
12. Graybill J.R. The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist Updat 3 (2000) 364-383
13. Steinbach W.J., and Perfect J.R. Newer antifungal therapy for emerging fungal pathogens. Int J Infect Dis 7 (2003) 5-20
14. Roffey S.J., Cole S., Comby P., et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31 (2003) 731-741
15. Sugar A.M., and Liu X.P. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 45 (2001) 601-604
16. Capilla J., Serena C., Pastor F.J., et al. Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother 47 (2003) 3976-3978
17. Graybill J.R., Najvar L.K., Gonzalez G.M., et al. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 51 (2003) 1373-1376
18. Clemons K.V., Espiritu M., Parmar R., et al. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 49 (2005) 4867-4875
19. Andes D., and Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43 (1999) 2116-2120